Marie-Claude Beauchamp

Marie-Claude Beauchamp

Auto-generated profile, based on publicly available information

Marie-Claude Beauchamp

Research Institute of the McGill University Health Centre at Glen Site, Montreal, QC H4A 3J1, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2010 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
MBMarie-Claude Beauchamp
Marie-Claude Beauchamp
AYAmber Yasmeen
Amber Yasmeen
AKAriane Knafo
Ariane Knafo
WGWalter H. Gotlieb
Walter H. Gotlieb
Ovarian cancer is the most lethal of all gynecological malignancies, due in part to the diagnosis at an advanced stage caused by the lack of specific signs and symptoms and the absence of reliable tests for screening and early detection. Most patients will respond initially to treatment but about 70% of them will suffer a recurrence. Therefore, new therapeutic modalities are urgently needed to overcome chemoresistance observed in ovarian cancer patients. Evidence accumulates suggesting that the insulin/insulin growth factor (IGF) pathways could act as a good therapeutic target in several cancers, including ovarian cancer. In this paper, we will focus on the role of insulin/IGF in ovarian cancer tumorigenesis and treatment.

18 February 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MBMarie-Claude Beauchamp
Marie-Claude Beauchamp
ADAnissa Djedid
Anissa Djedid
EBEric Bareke
Eric Bareke
FMFjodor Merkuri
Fjodor Merkuri
RARachel Aber
Rachel Aber
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
EFTUD2 is mutated in patients with mandibulofacial dysostosis with microcephaly (MFDM). We generated a mutant mouse line with conditional mutation in Eftud2 and used Wnt1-Cre2 to delete it in neural crest cells. Homozygous deletion of Eftud2 causes brain and craniofacial malformations, affecting the same precursors as in MFDM patients. RNAseq analysis of embryonic heads revealed a significant increase in exon skipping and increased levels of an alternatively spliced Mdm2 transcript lacking exon 3. Exon skipping in Mdm2 was also increased in O9-1 mouse neural crest cells after siRNA knock-down of Eftud2 and in MFDM patient cells. Moreover, we found increased nuclear P53, higher expression of P53-target genes and increased cell death. Finally, overactivation of the P53 pathway in Eftud2 knockdown cells was attenuated by overexpression of non-spliced Mdm2, and craniofacial development was improved when Eftud2-mutant embryos were treated with Pifithrin-α, an inhibitor of P53. Thus, our work indicates that the P53-pathway can be targeted to prevent craniofacial abnormalities and shows a previously unknown role for alternative splicing of Mdm2 in the etiology of MFDM.

30 November 2009 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
MBMarie-Claude Beauchamp
Marie-Claude Beauchamp
AKAriane Knafo
Ariane Knafo
AYAmber Yasmeen
Amber Yasmeen
JCJoan M. Carboni
Joan M. Carboni
MGMarco M. Gottardis
Marco M. Gottardis
WGWalter Gotlieb
Walter Gotlieb

22 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MBMarie-Claude Beauchamp
Marie-Claude Beauchamp
ADAnissa Djedid
Anissa Djedid
EBEric Bareke
Eric Bareke
FMFjodor Merkuri
Fjodor Merkuri
RARachel Aber
Rachel Aber
LJLoydie Jerome-Majewska
Loydie Jerome-Majewska
Summary: EFTUD2, a GTPase and core component of the splicesome, is mutated in patients with mandibulofacial dysostosis with microcephaly (MFDM). We generated a mutant mouse line with conditional mutation in Eftud2 and used Wnt1-Cre2 to delete it in neural crest cells. Homozygous deletion of Eftud2 leads to neural crest cell death and malformations in the brain and craniofacial region of embryos. RNAseq analysis of embryonic mutant heads revealed a significant increase in exon skipping, in retained introns and enriched levels of Mdm2 transcripts lacking exon 3. Mutants also had increased nuclear P53, higher expression of P53-target genes, and increased cell death. Their craniofacial development was significantly improved when treated with Pifithrin-α, an inihibitor of P53. We propose that craniofacial defects caused by mutations of EFTUD2 are a result of mis-splicing of Mdm2 and P53-associated cell death. Hence, drugs that reduce P53 activity may help prevent craniofacial defects associated with spliceosomopathies.